Cargando...
Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma
Sorafenib demonstrated a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC) in phase III trials. However, almost all the patients included in those trials exhibited well-preserved liver function (Child-Pugh A). The aim of this study was to describe our experience with soraf...
Gardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4487071/ https://ncbi.nlm.nih.gov/pubmed/26171182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.536 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|